This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by UCB Pharma Oy Finland.
American College of Rheumatology
Reference
Soini E, et al. Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland. Advances in Therapy : 3 Oct 2017. Available from: URL: http://doi.org/10.1007/s12325-017-0614-8
Rights and permissions
About this article
Cite this article
Certolizumab good choice for RA in Finland. PharmacoEcon Outcomes News 789, 13 (2017). https://doi.org/10.1007/s40274-017-4420-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-4420-y